Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan.

Authors :: Feemster KA
Kim Y
Abe M
Johnson K
Sasaki S
Source :: Expert review of vaccines [Expert Rev Vaccines] 2022 May; Vol. 21 (5), pp. 589-590. Date of Electronic Publication: 2022 Feb 16.
Publication Year :: 2022

Subjects :: Adult
Cost-Benefit Analysis
Humans
Japan epidemiology
Streptococcus pneumoniae
Pneumococcal Infections epidemiology
Pneumococcal Infections prevention & control

Full Text Access

Tools